



TRIDENT LIFELINE LIMITED
(Formerly Trident Lifeline Private Limited)

CIN No. : L51909GJ2014PLC078227
GST No. : 24AAECT8906D1ZG

Date: July 28, 2025

BSE Limited 14th Floor, P. J. Towers, Dalal Street, Fort, Mumbai – 400001.	Stock ID: TLL Scrip Code: 543616
--	---

Sub: Outcome of Board Meeting held on 28.07.2025

We wish to inform you that the Board of Directors, at their meeting held today-Monday, July 28, 2025, has transacted, approved, and taken on record the following items of Business;

1. Approval of Un-Audited Standalone and Consolidated Financial Results:

The Board of Directors inter-alia has approved and taken on record Un-Audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025. (The copy of Un-Audited Standalone & Consolidated Financial results along with Limited Review Report of Auditors thereon is attached herewith as **(Annexure-A)**).

Further, pursuant to the provisions of Regulation 47 of the SEBI Listing Regulations, an extract of the aforementioned Financial Results would be published in the newspapers in accordance with the SEBI Listing Regulations, and the same will be made available on the Company's website at <http://www.tridentlifeline.com/>.

2. Take note of various compliances made during the quarter ended June 30, 2025.

3. Appointment of Secretarial Auditor of the Company:

The Board of Directors has inter alia approved the Appointment of M/s. Amareliya & Associates, Practicing Company Secretary (COP No. 24321; PR: 4735/2023), Surat as Secretarial Auditor of the Company for first term of 5 (five) consecutive years commencing from the financial year 2025-26 till the financial year 2029- 30, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting of the Company.

The disclosure as required pursuant to provisions of Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31 2024, is annexed herewith as **Annexure-B**.



CIN No. : L51909GJ2014PLC078227

GST No. : 24AAECT8906D1ZG

TRIDENT LIFELINE LIMITED

(Formerly Trident Lifeline Private Limited)

The Board Meeting commenced at 05:00 p.m. and concluded at 06:15 p.m.

You are requested to kindly take the note of above on records.

Thanking You,s

Yours Faithfully

For **Trident Lifeline Limited**

Nikita Sharma
Company Secretary and Compliance Officer
M. No.: A60595

Encl: As Above



INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT

Limited Review Report on unaudited standalone financial results of Trident Lifeline Limited for the quarter ended 30th June, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors

TRIDENT LIFELINE LIMITED

2nd Floor, Shop-2004,
North Extension, Falsawadi,
Begumpura, Sahara Darwaja,
Surat, Gujarat - 395003

1. We have reviewed the accompanying statement of Unaudited Standalone Financial result of **TRIDENT LIFELINE LIMITED** for the quarter ended on 30th June, 2025. This Statement is responsibility of the Company's Management and has been approved by its Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the statement in accordance with the standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that cause us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements Regulations, 2015) including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place : Surat
Date : 28/07/2025

For A Bafna & Associates
Chartered Accountants
(Firm Reg. No:- 121901W)


Meet P Jain


CA Meet Prakashkumar Jain
Partner
M. NO. 195377
ICAI UDIN NO.:- 25195377BMHWMG1042

Standalone Profit And Loss Statement of Unaudited Financial Results for the 1st Quarter ended 30th June, 2025				
(Amount In Lacs)				
Particulars	Quarter Ended			Year Ended
	30.06.2025 Unaudited (CY Q1)	31.03.2025 Audited (PY Q4)	30.06.2024 Unaudited (PY Q1)	31.03.2025 Audited FY 2024-25
I. Revenue From Operations				
Net Sales/Income From Operations (Net of Taxes)	1,881.82	2,084.65	1,473.67	6,779.91
Other Income	53.65	161.19	47.29	314.08
TOTAL INCOME	1,935.48	2,245.84	1,520.96	7,094.00
II. EXPENSES				
Cost of Materials Consumed	1,144.80	562.80	660.62	3,285.59
Purchase of Stock-in-Trade	65.65	37.52	106.65	187.96
Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(184.84)	235.07	50.34	147.06
Employment Benefit Expenses	86.99	102.50	52.18	306.95
Financial Costs	32.58	45.72	20.15	122.83
Depreciation and Amortization Expenses	51.19	71.08	32.59	152.87
Other Expenses	276.52	589.60	196.17	1,100.16
TOTAL EXPENSES	1,472.89	1,644.30	1,118.70	5,303.42
III. Profit Before Exceptional and Extraordinary Items and Tax	462.59	601.54	402.26	1,790.58
IV. Exceptional Items	-	-	-	-
V. Profit Before Extraordinary Items and Tax	462.59	601.54	402.26	1,790.58
VI. Extraordinary Items	-	-	-	-
VII. Profit Before Tax	462.59	601.54	402.26	1,790.58
VIII. Tax Expense :				
(1) Current Tax	(115.00)	(119.53)	(101.00)	(425.00)
(2) MAT Credit	-	-	-	-
(3) Excess Tax Provision of Earlier Year	-	13.90	-	-
(4) Deferred Tax	-	(60.44)	-	(60.44)
IX. Net Profit/(Loss) for the Period	347.59	435.47	301.26	1,305.14
X. Paid Up Equity Share Capital (FV:- Rs. 10/- each)	1,149.92	1,149.92	1,149.92	1,149.92
XI. Earning Per Equity Share:				
(1) Basic- Not Annualized	3.02	3.79	2.62	11.35
(2) Diluted- Not Annualized	3.02	3.79	2.62	11.35

For And On Behalf Of The Board

TRIDENT LIFELINE LIMITED


Chairman &
Executive Director
Hardik Desai
(DIN No: 01358227)


Managing
Director
Shravan H. Patel
(DIN No: 08629141)

Place : Surat

Date : 28th July, 2025

Notes to Financial Results

1. The above financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards specified under section 133 of the Act read with Companies (Accounting Standards) Rules, 2021 and the relevant provisions of the Companies Act 2013.
2. The above Financial Results of the company for the quarter ended as on 30th June, 2025 has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 28th, 2025.
3. Figures for the Previous periods have been re-grouped/re-stated/re-arranged, wherever necessary, to correspond with the current period's classification/disclosure/comparatives for the ease of the investor's or stakeholder's analysis.
4. As per management's current assessment, no significant impact on carrying amounts of inventories, trade receivables, investments and other financial assets is expected, and management will continue to monitor changes in future economic conditions. The eventual outcome of the impact of the global health pandemic may be different from those estimated as on the date of approval of these Standalone Financial statements.
5. As the company is listed on SME Platform of BSE, it has been exempted from the applicability of IND-AS as per the proviso to the rule 4 of Companies (Indian Accounting Standards), 2015
6. The status of Investor's Complaints during the year ended on 30th June, 2025 is as under:


Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed of and resolved during the period	Nil
Complaints pending at the end of the period	Nil

For Trident Lifeline Limited

For Trident Lifeline Limited



Hardik Desai
Chairman & Executive Director
DIN:- 01358227



Shravan H. Patel
Managing Director
DIN:- 08629141



INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT

Independent Auditor's Review Report on unaudited consolidated financial results of Trident Lifeline Limited for the quarter ended on 30th June, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of

TRIDENT LIFELINE LIMITED

2nd Floor, Shop-2004,
North Extension, Falsawadi,
Begumpura, Sahara Darwaja,
Surat, Gujarat - 395003

1. We have reviewed the accompanying statement of unaudited consolidated financial result of **TRIDENT LIFELINE LIMITED** and its subsidiaries **TNS PHARMA PRIVATE LIMITED, TLL PARENTERALS LIMITED, TRIDENT MEDIQUIP LIMITED, TLL ELEMENTS PRIVATE LIMITED & TLL HERBAL LIMITED** (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended on 30th June, 2025 and for the period from 01st April, 2025 to 30th June, 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended on 30th June, 2025 and the corresponding period from 01st April, 2025 to 30th June, 2025, as reported in these financial results have been approved by the Parent's Board of Directors.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.





A Bafna & Associates

CHARTERED ACCOUNTANTS

4. The Statement includes the results of the following entities:

- a) M/s. Trident Lifeline Limited (The parent company)
- b) M/s. TNS Pharma Private Limited (The subsidiary company)
- c) M/s. TLL Parenterals Limited (The subsidiary company)
- d) M/s. Trident Mediquip Limited (The subsidiary company)
- e) M/s. TLL Elements Private Limited (The subsidiary company)
- f) M/s. TLL Herbal Limited (The subsidiary company)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Surat
Date : 28/07/2025



For A Bafna & Associates
Chartered Accountants
(Firm Reg. No:- 121901W)

Meet P Jain

CA Meet Prakashkumar Jain
Partner

M. NO. 195377

UDIN NO.:- 25195377BMHWMH1215

Consolidated Profit And Loss Statement of Unaudited Financial Results for the Quarter ended 30th June, 2025


(Amount In Lacs)

Particulars	Quarter Ended			Year Ended
	30.06.2025 Unaudited (CY Q1)	31.03.2025 Audited (PY Q4)	30.06.2024 Unaudited (PY Q1)	31.03.2025 Audited FY 2024-25
I. Revenue From Operations				
Net Sales/Income From Operations (Net of Taxes)	2,360.54	3,401.07	1,315.40	8,696.47
Other Income	135.37	187.41	115.06	823.11
TOTAL INCOME	2,495.90	3,588.48	1,430.45	9,519.58
II. EXPENSES				
Cost of Materials Consumed	1,178.11	1,920.02	663.10	4,304.63
Purchase of Stock-in-Trade	205.43	(230.54)	83.19	179.59
Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(288.96)	86.13	23.42	71.00
Employment Benefit Expenses	268.43	393.62	110.39	1,208.84
Financial Costs	112.63	154.65	49.37	398.52
Depreciation and Amortization Expenses	146.04	274.24	54.37	549.25
Other Expenses	480.79	378.95	185.52	1,446.27
TOTAL EXPENSES	2,102.48	2,977.08	1,169.36	8,158.10
III. Profit Before Exceptional and Extraordinary Items and Tax	393.43	611.40	261.09	1,361.49
IV. Exceptional Items	-	-	-	-
V. Profit Before Extraordinary Items and Tax	393.43	611.40	261.09	1,361.49
VI. Extraordinary Items	-	-	-	-
VII. Profit Before Tax	393.43	611.40	261.09	1,361.49
VIII. Tax Expense :				
(1) Current Tax	(115.00)	(139.33)	(101.00)	(453.80)
(2) MAT Credit	-	-	-	-
(3) Excess Tax Provision of Earlier Year	-	(0.38)	-	(0.38)
(4) Deferred Tax	-	142.18	-	142.18
IX. Net Profit/(Loss) for the Period	278.43	613.87	160.09	1,049.48
Minority Interest	(27.85)	(93.48)	(69.17)	(125.31)
Profit for the Year after Minority Interest	306.28	707.35	229.26	1,174.79
Profit/(Loss) From Discontinuing Operations	-	-	-	-
Tax Expense of Discounting Operations	-	-	-	-
Profit/(Loss) From Discontinuing Operations	-	-	-	-
Balance Transferred to Pre-operative Expenses	-	-	-	-
Profit/(Loss) For The Period	306.28	707.35	229.26	1,174.79
X. Paid Up Equity Share Capital (FV:- Rs. 10/- each)	1,149.92	1,149.92	1,149.92	1,149.92
XI. Earning Per Equity Share:				
(1) Basic- Not Annualized	2.66	6.15	1.99	10.22
(2) Diluted- Not Annualized	2.66	6.15	1.99	10.22

For And On Behalf Of The Board
TRIDENT LIFELINE LIMITED


 Chairman &
 Executive Director

Hardik Desai
 (DIN No: 01358227)


 Managing
 Director


Shravan H. Patel
 (DIN No: 08629141)

Notes to Financial Results

1. The above financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards specified under section 133 of the Act read with Companies (Accounting Standards) Rules, 2021 and the relevant provisions of the Companies Act 2013.
2. The above Financial Results of the company for the quarter ended on 30th June, 2025 has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 28th July, 2025.
3. Figures for the Previous periods have been re-grouped/re-stated/re-arranged, wherever necessary, to correspond with the current period's classification/disclosure/ comparatives for the ease of the investor's or stakeholder's analysis.
4. M/s. Trident Lifeline Limited has acquired 51%, 51%, 100%, 51% & 51% shareholding of M/s. TNS Pharma Pvt. Ltd., M/s. TLL Parenterals Ltd., M/s. TLL Elements Private Ltd., M/s. Trident Mediquip Ltd. & M/s. TLL Herbal Ltd. respectively and became holding company as on 21/12/2022, 02/12/2024, 15/04/2024, 04/02/2025 & 10/08/2023 respectively. Hence, we have prepared Consolidated Financial Statements of M/s. Trident Lifeline Limited as on 30/06/2025 (Quarter ended) by consolidating above-mentioned portion of Assets and Liabilities of M/s. TNS Pharma Pvt. Ltd., M/s. TLL Parenterals Ltd., M/s. TLL Elements Private Ltd., M/s. Trident Mediquip Ltd. & M/s. TLL Herbal Ltd. respectively.
5. As per management's current assessment, no significant impact on carrying amounts of inventories, trade receivables, investments and other financial assets is expected, and management will continue to monitor changes in future economic conditions. The eventual outcome of the impact of the global health pandemic may be different from those estimated as on the date of approval of these Consolidated Financial statements.
6. As the company is listed on SME Platform of BSE, it has been exempted from the applicability of IND-AS as per the proviso to the rule 4 of Companies (Indian Accounting Standards), 2015
7. The status of Investor's Complaints during the year ended on 30th June, 2025 is as under:


Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed of and resolved during the period	Nil
Complaints pending at the end of the period	Nil

For Trident Lifeline Limited



Hardik Desai
Chairman & Executive Director
DIN:- 01358227

For Trident Lifeline Limited



Shravan H. Patel
Managing Director
DIN:- 08629141

Annexure-B

Disclosure of information pursuant to Regulation 30 of SEBI LODR Regulations
read with SEBI
circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31,
2024

Particulars	
Name	M/s. Amareliya & Associates, Practicing Company Secretary (ICSI M. No. F12452; COP: 24321; PR No.: 4735/2023)
Reason for Change viz. Appointment, Resignation, Removal, Death or otherwise;	Appointment as the Secretarial Auditors of the Company for first term of 5 (five) consecutive years commencing from the financial year 2025-26 till the financial year 2029-30, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting of the Company
Date of appointment/cessation (as applicable) & term of appointment	28 th July, 2025 subject to approval of the shareholders of the Company at the ensuing Annual General Meeting of the Company Term: First term of 5 (five) consecutive years commencing from the financial year 2025-26 till the financial year 2029-30
Brief Profile (in case of appointment)	Field of Experience: Experience in providing Secretarial Audit services, have more than seven years post qualification experience including more than 4 years of experience in the practicing field. The area of practice includes Advisory services in company law matters, Company Law Compliance, Listing Compliance, Advisor/ consultant in issue of Shares and Other Securities by the companies, Income Tax Compliances, GST Compliances, Trademark Consultancy etc.
Disclosure of Relationship between Directors (In case Appointment of Director)	NIL